|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
|
US6846839B1
(en)
|
1995-06-07 |
2005-01-25 |
Sugen, Inc. |
Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
|
|
AR012634A1
(es)
*
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
|
US6235769B1
(en)
|
1997-07-03 |
2001-05-22 |
Sugen, Inc. |
Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
|
|
US6569868B2
(en)
|
1998-04-16 |
2003-05-27 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
|
IL139934A
(en)
|
1998-05-29 |
2007-10-31 |
Sugen Inc |
History 2 - Indulinone converted to pyrrole and pharmaceutical preparations containing them
|
|
US6248363B1
(en)
*
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
|
JP2002539262A
(ja)
*
|
1999-03-19 |
2002-11-19 |
パーカー ヒューズ インスティテュート |
キナゾリン化合物製剤および治療におけるその使用
|
|
US7064114B2
(en)
|
1999-03-19 |
2006-06-20 |
Parker Hughes Institute |
Gel-microemulsion formulations
|
|
DE60012718T2
(de)
*
|
1999-04-09 |
2005-10-20 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Prognose von ptp lar vermittelten krankheiten
|
|
DE60036812T2
(de)
|
1999-07-07 |
2008-07-17 |
Astrazeneca Uk Ltd. |
Chinazolin derivate
|
|
GB9925127D0
(en)
*
|
1999-10-22 |
1999-12-22 |
Pharmacia & Upjohn Spa |
Oral formulations for anti-tumor compounds
|
|
US6878733B1
(en)
|
1999-11-24 |
2005-04-12 |
Sugen, Inc. |
Formulations for pharmaceutical agents ionizable as free acids or free bases
|
|
JP2003535038A
(ja)
*
|
1999-12-30 |
2003-11-25 |
スージェン・インコーポレーテッド |
蛋白質キナーゼ活性の調節および癌化学療法において用いるための３−ヘテロアリーリデニル−２−インドリノン化合物
|
|
DE122008000002I1
(de)
|
2000-02-15 |
2008-04-17 |
Sugen Inc |
Pyrrol substituierte indolin-2-on protein kinase inhibitoren
|
|
JP2003525897A
(ja)
|
2000-03-06 |
2003-09-02 |
アストラゼネカ アクチボラグ |
治 療
|
|
TWI270545B
(en)
|
2000-05-24 |
2007-01-11 |
Sugen Inc |
Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
|
CA2410509A1
(en)
|
2000-06-02 |
2001-12-13 |
Sugen, Inc. |
Indolinone derivatives as protein kinase/phosphatase inhibitors
|
|
DE60136459D1
(de)
|
2000-06-24 |
2008-12-18 |
Astrazeneca Ab |
Guanidin-derivate von chinazoin zur behandlung von autoimmunkrankheiten
|
|
WO2002002534A1
(en)
*
|
2000-07-03 |
2002-01-10 |
Astrazeneca Ab |
Quinazolines with therapeutic use
|
|
JP2004504342A
(ja)
*
|
2000-07-24 |
2004-02-12 |
ファルマシア・アンド・アップジョン・カンパニー |
極めて水不溶性の脂肪親和性薬剤用の自己乳化性ドラッグデリバリーシステム
|
|
AU2001284772A1
(en)
*
|
2000-08-10 |
2002-02-25 |
Delsys Pharmaceutical Corporation |
Improved solid pharmaceutical dosage formulation of hydrophobic drugs
|
|
US20030031715A1
(en)
*
|
2000-10-11 |
2003-02-13 |
Kinam Park |
Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof
|
|
US20050158271A1
(en)
*
|
2000-10-11 |
2005-07-21 |
Lee Sang C. |
Pharmaceutical applications of hydrotropic polymer micelles
|
|
AR042586A1
(es)
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
|
|
WO2002069936A2
(en)
*
|
2001-03-02 |
2002-09-12 |
Dr. Reddy's Laboratories Ltd. |
Pharmaceutical composition of ibuprofen
|
|
US6912582B2
(en)
|
2001-03-30 |
2005-06-28 |
Microsoft Corporation |
Service routing and web integration in a distributed multi-site user authentication system
|
|
AU2002303892A1
(en)
|
2001-05-30 |
2002-12-09 |
Jingrong Cui |
5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
|
|
US6720002B2
(en)
*
|
2001-07-20 |
2004-04-13 |
R.P. Scherer Technologies, Inc. |
Antihistamine formulations for soft capsule dosage forms
|
|
GB0126433D0
(en)
*
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
|
CA2466807A1
(en)
*
|
2001-11-21 |
2003-06-05 |
Sugen, Inc. |
Pharmaceutical formulations comprising indolinone derivatives
|
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
|
US20030139386A1
(en)
*
|
2001-12-21 |
2003-07-24 |
Sophie Cote |
Pharmaceutical compositions based on azetidine derivatives
|
|
RS63204A
(sr)
*
|
2002-01-17 |
2006-10-27 |
Neurogen Corporation |
Supstituisani analozi hinazolin-4-ilamina kao modulatori kapsaicina
|
|
BR0307721A
(pt)
*
|
2002-02-15 |
2005-01-25 |
Upjohn Co |
Processo para preparação de derivados de indolinona
|
|
MY135609A
(en)
*
|
2002-02-26 |
2008-05-30 |
Astrazeneca Ab |
Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
|
|
US7071216B2
(en)
*
|
2002-03-29 |
2006-07-04 |
Chiron Corporation |
Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
|
|
US8299108B2
(en)
*
|
2002-03-29 |
2012-10-30 |
Novartis Ag |
Substituted benzazoles and methods of their use as inhibitors of raf kinase
|
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
|
WO2003091224A1
(en)
|
2002-04-26 |
2003-11-06 |
Nippon Shinyaku Co., Ltd. |
Quinazoline derivative and medicine
|
|
AR042461A1
(es)
*
|
2002-12-13 |
2005-06-22 |
Neurogen Corp |
Analogos 2-sustituidos de quinazolin-4-il - amina. composiciones farmaceuticas
|
|
ITRM20030074A1
(it)
*
|
2003-02-21 |
2004-08-22 |
Pharmacia Italia Spa |
Formulazioni semisolide a rilascio immediato intese
|
|
ES2423800T3
(es)
*
|
2003-03-28 |
2013-09-24 |
Novartis Vaccines And Diagnostics, Inc. |
Uso de compuestos orgánicos para la inmunopotenciación
|
|
DE602004004259T2
(de)
|
2003-04-16 |
2007-11-15 |
F. Hoffmann-La Roche Ag |
(6-(PHENOXY)-PYRIDOi3,4-DöPYRIMIDIN-2-YL)-AMIN DERIVATE ALS P38 KINASE INHIBITOREN ZUR BEHANDLUNG VON ENTZÜNDLICHEN ERKRANKUNGEN WIE RHEUMATOIDER ARTHRITIS
|
|
CA2522522A1
(en)
|
2003-04-16 |
2004-10-28 |
F. Hoffmann-La Roche Ag |
Quinazoline compounds
|
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US7329664B2
(en)
*
|
2003-07-16 |
2008-02-12 |
Neurogen Corporation |
Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
|
|
GB0317663D0
(en)
*
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Pharmaceutical composition
|
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
|
MXPA06002964A
(es)
|
2003-09-16 |
2006-06-14 |
Astrazeneca Ab |
Derivados de quinazolina como inhibidores de cinasa de tirosina.
|
|
DE602004021838D1
(de)
*
|
2003-10-16 |
2009-08-13 |
Novartis Vaccines & Diagnostic |
Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
|
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US7491263B2
(en)
|
2004-04-05 |
2009-02-17 |
Technology Innovation, Llc |
Storage assembly
|
|
NZ550796A
(en)
|
2004-05-06 |
2010-07-30 |
Warner Lambert Co |
4-phenylamino-quinazolin-6-yl-amides
|
|
US20050256097A1
(en)
*
|
2004-05-11 |
2005-11-17 |
Kosan Biosciences, Inc. |
Pharmaceutical solution formulations containing 17-AAG
|
|
JP5001150B2
(ja)
|
2004-06-08 |
2012-08-15 |
ファミリーズ オブ スパイナル マスキュラー アトロフィー |
脊髄性筋萎縮症のための２，４−ジアミノキナゾリン
|
|
KR100915481B1
(ko)
*
|
2004-11-09 |
2009-09-03 |
에프. 호프만-라 로슈 아게 |
아미노퀴나졸린 화합물
|
|
WO2006064196A1
(en)
|
2004-12-14 |
2006-06-22 |
Astrazeneca Ab |
Pyrazolopyrimidine compounds as antitumor agents
|
|
WO2006102157A1
(en)
*
|
2005-03-21 |
2006-09-28 |
Ivax Pharmaceuticals S.R.O. |
Crystallization inhibitor and its use in gelatin capsules
|
|
US7820683B2
(en)
|
2005-09-20 |
2010-10-26 |
Astrazeneca Ab |
4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
PT1971338E
(pt)
*
|
2005-12-22 |
2011-05-09 |
Astrazeneca Ab |
Combina??o de zd6474 e pemetrexed
|
|
US20070167422A1
(en)
*
|
2006-01-18 |
2007-07-19 |
Yu Kwok S |
Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
|
|
US20070287707A1
(en)
*
|
2006-02-28 |
2007-12-13 |
Arrington Mark P |
Phosphodiesterase 10 inhibitors
|
|
EP2615086A1
(en)
|
2006-08-01 |
2013-07-17 |
Families of Spinal Muscular Atrophy |
2,4-Diaminoquinazolines for the treatment of spinal muscular atrophy
|
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
|
EA200901041A1
(ru)
|
2007-02-06 |
2010-02-26 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
|
|
WO2009042114A2
(en)
|
2007-09-21 |
2009-04-02 |
The Johns Hopkins University |
Phenazine derivatives and uses thereof
|
|
JP5336516B2
(ja)
|
2008-02-07 |
2013-11-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
スピロ環式複素環化合物、該化合物を含む医薬品、その使用及びその製造方法
|
|
US8861813B2
(en)
*
|
2008-03-13 |
2014-10-14 |
Mallinckrodt Llc |
Multi-function, foot-activated controller for imaging system
|
|
BRPI0912170A2
(pt)
|
2008-05-13 |
2015-10-13 |
Astrazeneca Ab |
composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
|
|
CA2733153C
(en)
|
2008-08-08 |
2016-11-08 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
|
US11304960B2
(en)
|
2009-01-08 |
2022-04-19 |
Chandrashekar Giliyar |
Steroidal compositions
|
|
JP5359333B2
(ja)
*
|
2009-02-05 |
2013-12-04 |
ゼリア新薬工業株式会社 |
コロソリン酸含有水性液剤
|
|
PL2401267T3
(pl)
*
|
2009-02-27 |
2014-06-30 |
Ambit Biosciences Corp |
Pochodne chinazoliny modulujące kinazę JAK i ich zastosowanie w metodach
|
|
EP3575288B1
(en)
|
2009-09-03 |
2021-10-27 |
Bristol-Myers Squibb Company |
Quinazolines as potassium ion channel inhibitors
|
|
MX337893B
(es)
*
|
2009-11-10 |
2016-03-28 |
Celgene Corp |
Nanosuspension de un farmaco debilmente soluble preparada por un proceso de microfluidizacion.
|
|
US20180153904A1
(en)
|
2010-11-30 |
2018-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
|
US20120148675A1
(en)
|
2010-12-10 |
2012-06-14 |
Basawaraj Chickmath |
Testosterone undecanoate compositions
|
|
CN102716103B
(zh)
*
|
2012-07-02 |
2013-12-18 |
西安力邦制药有限公司 |
2,2′,6,6′-四异丙基-4,4′-二联苯酚软胶囊制剂及其制备方法
|
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
|
CN103837615B
(zh)
*
|
2014-02-15 |
2015-05-20 |
青岛农业大学 |
一种应用高效液相色谱法同时测定植物蜕皮激素类物质的方法
|
|
US20170246187A1
(en)
|
2014-08-28 |
2017-08-31 |
Lipocine Inc. |
(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
|
|
US9498485B2
(en)
|
2014-08-28 |
2016-11-22 |
Lipocine Inc. |
Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
|
|
UY36294A
(es)
|
2014-09-12 |
2016-04-29 |
Novartis Ag |
Compuestos y composiciones como inhibidores de quinasa
|
|
US20160361322A1
(en)
|
2015-06-15 |
2016-12-15 |
Lipocine Inc. |
Composition and method for oral delivery of androgen prodrugs
|
|
WO2018051306A1
(en)
|
2016-09-19 |
2018-03-22 |
Novartis Ag |
Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
|
|
US11559530B2
(en)
|
2016-11-28 |
2023-01-24 |
Lipocine Inc. |
Oral testosterone undecanoate therapy
|
|
KR20240032157A
(ko)
|
2017-05-02 |
2024-03-08 |
노파르티스 아게 |
병용 요법
|
|
EP3824296A4
(en)
|
2018-07-20 |
2022-04-27 |
Lipocine Inc. |
LIVER DISEASE
|
|
MX2021013817A
(es)
|
2019-05-13 |
2021-12-14 |
Novartis Ag |
Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.
|
|
WO2021216928A1
(en)
*
|
2020-04-22 |
2021-10-28 |
Scienture, Inc. |
Long-acting bupivacaine microsphere formulations
|
|
CN113398067B
(zh)
*
|
2021-07-19 |
2022-08-16 |
宁波三生生物科技股份有限公司 |
一种四烯雌酮注射液及其制备方法和应用
|